NVOS Earning Report: Revenue, Losses & Filing Dates
If you are searching for the NVOS earnings report, you probably want three things: how much revenue Novo Integrated Sciences makes, how big the losses are, and when the next report is due. This page covers all three, using the company’s own annual filings.
One warning first. NVOS trades on the OTC Pink market at a very low price, and its reports tend to move the stock more than they would for a large company. Read the numbers below as background, not as a reason to buy or sell.
What Is the NVOS Earning Report?
The NVOS earning report is the set of financial results Novo Integrated Sciences files with the SEC. The company runs a Canadian healthcare business. It operates 14 corporate-owned clinics offering physiotherapy, chiropractic care and related services. It also sells health and wellness products, which made up about 37% of revenue in fiscal 2024.
Its fiscal year ends on August 31, not December 31. That trips up a lot of people. The annual 10-K lands in the winter, and the quarterly 10-Q filings come in between. If you want the exact calendar, our page on the NVOS earnings date tracks the filing schedule.
If you are new to the company itself, start with this overview of Novo Integrated Sciences before going through the figures.
NVOS Earning Report: Annual Results at a Glance
Here are the last three annual results I could confirm from the company’s 10-K filings.
| Fiscal Year (ended Aug 31) | Revenue | Gross Profit | Net Loss |
| 2022 | $11.74M | $4.80M | $33.05M |
| 2023 | $12.57M | $4.95M | $13.27M |
| 2024 | $13.29M | $5.74M | $16.13M |
Source: Novo Integrated Sciences Form 10-K filings on SEC EDGAR.
A few things stand out.
Revenue has grown every year. It rose from about $11.7 million to $13.3 million over this stretch. That is steady, but small.
Losses are much bigger than the business. In fiscal 2024 the company lost more than it earned in total revenue. The net loss was $16.13 million against $13.29 million in sales.
2022 was distorted by write-downs. The $33 million loss that year included roughly $14 million of asset impairment plus another $1.4 million of goodwill impairment. It was not all day-to-day operating pain, though the operating loss was still large.
Per-Share Numbers and the Reverse Split
Earnings per share (EPS) is the line most traders look at first. NVOS reported a loss of $0.89 per share for fiscal 2024, compared with a loss of $1.30 per share the year before.
Be careful when comparing older figures. The company did a 1-for-10 reverse stock split on November 6, 2023, so per-share numbers from before that date look very different in restated filings. If an old chart shows a much smaller loss per share, check whether it was adjusted for the split.
| Metric | FY2023 | FY2024 |
| Net loss per share | $(1.30) | $(0.89) |
| Shares outstanding | 15.76M | 19.05M |
| Loss from operations | $(8.55M) | $(10.08M) |
The share count grew by more than three million in a year. That dilution matters. Even if the company narrows its losses, each existing share owns a smaller slice.
Why the NVOS Earning Report Moves the Stock
For a company this size, a filing can matter for reasons beyond profit.
- Going concern language: Auditors sometimes flag doubt about whether a company can keep operating. Read that section of every 10-K.
- Financing: Small caps often raise money through notes and share issuances. NVOS issued promissory notes in 2024, which it reported as repaid by August 31, 2024.
- Late filings: Missing a deadline can hurt sentiment on its own.
- Thin volume: With very few shares trading on some days, any news can swing the price hard.
For a wider look at price swings, read our breakdown of NVOS stock price volatility.
Where to Check the Latest NVOS Earning Report
Do not rely on a single aggregator. Several sites I checked show blank or outdated figures for NVOS, and some list the stock on the wrong exchange. The primary sources are better.
- SEC EDGAR: Search for Novo Integrated Sciences and open the latest 10-K or 10-Q. This is the official record.
- The company’s investor page: Press releases usually appear here first.
- OTC Markets: Check the NVOS profile for filing status and disclosure tier.
Once you have the raw numbers, you can see how others read them. Our NVOS stock forecast and NVOS stock price target pages cover outlook and risks. For crowd sentiment after a filing, see Stock Twits NVOS and the NVOS message board. New to those platforms? Here is what StockTwits is and how it works.
How to Read an NVOS Earnings Filing Without Getting Lost
Filings are long. You do not need all of it. Check these four things in order:
- Revenue and gross profit. Is the core clinic business growing?
- Net loss and operating loss. Is the gap getting smaller?
- Cash and debt. How long can the company fund itself?
- Share count. Did it rise again?
If revenue grows while losses shrink and share count stays flat, that is a healthier picture. NVOS has shown the first part for three years. The other two have been harder to fix.
FAQs About the NVOS Earning Report
When does NVOS report earnings?
Novo Integrated Sciences has a fiscal year ending August 31. The annual 10-K has typically been filed in December, for example on December 18, 2024. See the NVOS earnings date page for the schedule.
What was NVOS revenue in fiscal 2024?
Revenue was $13.29 million, up from $12.57 million in fiscal 2023, according to the company’s 10-K.
Is NVOS profitable?
No. The company posted a net loss of $16.13 million in fiscal 2024 and has reported losses in each of the years shown above.
Does NVOS beat or miss earnings estimates?
Most data providers show no analyst consensus for NVOS, so “beat” or “miss” labels are usually blank. Coverage of tiny OTC stocks is thin.
Does NVOS pay a dividend?
No. Data providers list no dividend for the stock.
Where can I find the official NVOS earning report?
Use SEC EDGAR and search for Novo Integrated Sciences. Filings there are the official record.
Is this financial advice?
No. This article is general information. Check the latest filings and speak with a licensed advisor before making any trade.
Conclusion
The NVOS earning report tells a simple story. Novo Integrated Sciences has grown revenue from $11.7 million to $13.3 million across three fiscal years, but it keeps losing more than it brings in, and its share count keeps climbing. That combination is why the stock is so volatile.
Before you act on any headline, open the latest 10-K or 10-Q on SEC EDGAR, check the filing date, and compare the new numbers with the table above. Then read the NVOS stock forecast for context on the risks.
